Shaping of iNKT cell repertoire after unrelated cord blood transplantation

Clinical Immunology

Volumn 135, Issue 3, 2010, Pages 364-373

  Beziat, Vivien ^a,b   Nguyen, Stéphanie ^a,b   Exley, Mark ^c   Achour, Abla ^a,b   Simon, Tabassonne ^d   Chevallier, Patrice ^e   Sirvent, Anne ^f   Vigouroux, Stéphane ^g   Debré, Patrice ^a,b   Rio, Bernard ^h   Vieillard, Vincent ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HÔPITAL SAINT ANTOINE   (France)

^e HÔTEL DIEU   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h HÔTEL DIEU   (France)

Author keywords

AML; CD1d expression; iNKT cells; Reconstitution

Indexed keywords

CD1D ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR7; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; L SELECTIN; NATURAL KILLER CELL RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; IMMUNOREGULATION; INVARIANT NATURAL KILLER T CELL; NATURAL KILLER T CELL; PHENOTYPE; PRIORITY JOURNAL;

CELL DIFFERENTIATION; CELL SEPARATION; CORD BLOOD STEM CELL TRANSPLANTATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; NATURAL KILLER T-CELLS; PHENOTYPE;

EID: 77951966711     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.01.010     Document Type: Article

References (55)

1. Exley M., Garcia J., Balk S.P., and Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J. Exp. Med. 186 (1997) 109-120
2. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23 (2005) 877-900
3. Bendelac A., Savage P.B., and Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 25 (2007) 297-336
4. Van Kaer L. NKT cells: T lymphocytes with innate effector functions. Curr. Opin. Immunol. 19 (2007) 354-364
5. Hayday A.C. Gamma/delta cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18 (2000) 975-1026
6. Treiner E., and Lantz O. CD1d- and MR1-restricted invariant T cells: of mice and men. Curr. Opin. Immunol. 18 (2006) 519-526
7. Gumperz J.E., Miyake S., Yamamura T., and Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195 (2002) 625-636
8. Lee P.T., Benlagha K., Teyton L., and Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J. Exp. Med. 195 (2002) 637-641
9. Gluckman E., Rocha V., Boyer-Chammard A., Locatelli F., Arcese W., Pasquini R., Ortega J., Souillet G., Ferreira E., Laporte J.P., Fernandez M., and Chastang C. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N. Engl. J. Med. 337 (1997) 373-381
10. Rocha V., Labopin M., Sanz G., Arcese W., Schwerdtfeger R., Bosi A., Jacobsen N., Ruutu T., de Lima M., Finke J., Frassoni F., and Gluckman E. Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry, Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N. Engl. J. Med. 351 (2004) 2276-2285
11. Laughlin M.J., Eapen M., Rubinstein P., Wagner J.E., Zhang M.J., Champlin R.E., Stevens C., Barker J.N., Gale R.P., Lazarus H.M., HM M.D., van Rood J.J., Scaradavou A., and Horowitz M.M. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N. Engl. J. Med. 351 (2004) 2265-2275
12. Nguyen S., Dhedin N., Vernant J.P., Kuentz M., Al Jijakli A., Rouas-Freiss N., Carosella E.D., Boudifa A., Debré P., and Vieillard V. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 105 (2005) 4135-4142
13. Beziat V., Nguyen S., Lapusan S., Hervier B., Dhedin N., Bories D., Uzunov M., Boudifa A., Trebeden-Negre H., Norol F., Marjanovic Z., Marie J.P., Vernant J.P., Debre P., Rio B., and Vieillard V. Fully functional NK cells after unrelated cord blood transplantation. Leukemia 23 (2009) 721-728
14. Cooley S., Xiao F., Pitt M., Gleason M., McCullar V., Bergemann T.L., McQueen K.L., Guethlein L.A., Parham P., and Miller P.J.S. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110 (2007) 578-586
15. Ruggeri L., Mancusi A., Burchielli E., Aversa F., Martelli M.F., and Velardi A. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr. Opin. Oncol. 19 (2007) 142-147
16. Barge R.M., Brouwer R.E., Beersma M.F., Starrenburg C.W., Zwinderman A.H., Hale G., Waldmann H., den Ottolander G.J., Falkenburg J.H., Willemze R., and Fibbe W.E. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome. Bone Marrow Trans. 27 (2001) 1053-1058
17. Chakraverty R., Rabin N., Peggs K., Robinson S., Duncan J.R., and Yong K. Dermatomyositis and sarcoid-like reaction associated with multiple myeloma treated effectively by high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Trans. 27 (2001) 1215-1217
18. Bethge W.A., Haegele M., Faul C., Lang P., Schumm M., Bornhauser M., Handgretinger R., and Kanz L. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp. Hematol. 34 (2006) 1746-1752
19. Nguyen S., Kuentz M., Vernant J.P., Dhedin N., Bories D., Debré P., and Vieillard V. Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation. Leukemia 22 (2008) 344-352
20. Morecki S., Panigrahi S., Pizov G., Yacovlev E., Gelfand Y., Eizik O., and Slavin S. Effect of KRN7000 on induced graft-vs-host disease. Exp. Hematol. 32 (2004) 630-637
21. Hashimoto D., Asakura S., Miyake S., Yamamura T., Van Kaer L., Liu C., Animoto M., and Teshima T. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J. Immunol. 174 (2005) 551-556
22. Morris E.S., MacDonald K.P., Rowe V., Banovic T., Kuns R.D., Don A.L., Bofinger H.M., Burman A.C., Olver S.D., Kienzle N., Porcelli S.A., Pellicci D.G., Godfrey D.I., Smyth M.J., and Hill G.R. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J. Clin. Invest. 115 (2005) 3093-3103
23. Zeng D., Gazit G., Dejbakhsh-Jones S., Balk S.P., Snapper S., Taniguchi M., and Strober S. Heterogeneity of NK1.1+ T cells in the bone marrow: divergence from the thymus. J. Immunol. 163 (1999) 5338-5345
24. Pillai A.B., George T.I., Dutt S., Teo P., and Strober S. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J. Immunol. 178 (2007) 6242-6251
25. Morris E.S., MacDonald K.P., Kuns R.D., Morris H.M., Banovic T., Don A.L., Rowe V., Wilson Y.A., Raffelt N.C., Engwerda C.R., Burman A.C., Markey K.A., Godfrey D.I., Smyth M.J., and Hill G.R. Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation. Nat. Med. 15 (2009) 436-441
26. Barker J.N., Weisdorf D.J., DeFor T.E., Blazar B.R., Miller J.S., and Wagner J.E. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102 (2003) 1915-1919
27. Exley M.A., He Q., Cheng O., Wang R.J., Cheney C.P., Balk S.P., and Koziel M.J. Cutting edge: compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J. Immunol. 168 (2002) 1519-1523
28. Exley M.A., Hou R., Shaulov A., Tonti E., Dellabona P., Casorati G., Akbari O., Akman H.O., Greenfield E.A., Gumperz J.E., Boyson J.E., Balk S.P., and Wilson S.B. Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur. J. Immunol. 38 (2008) 1756-1766
29. Yoneda K., Morii T., Nieda M., Tsukaguchi N., Amano I., Tanaka H., Yagi H., Narita N., and Kimura H. The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk. Res. 29 (2005) 147-152
30. Eger K.A., Sundrud M.S., Motsinger A.A., Tseng M., Van Kaer L., and Unutmaz D. Human natural killer T cells are heterogeneous in their capacity to reprogram their effector functions. PLoS ONE 1 (2006) e50
31. van Der Vliet H.J., Nishi N., de Gruijl T.D., von Blomberg B.M., van den Eertwegh A.J., Pinedo H.M., Giaccone G., and Scheper R.J. Human natural killer T cells acquire a memory-activated phenotype before birth. Blood 95 (2000) 2440-2442
32. D'Andrea A., Goux D., De Lalla C., Koezuka Y., Montagna D., Moretta A., Dellabona P., Casorati G., and Abrignani S. Neonatal invariant Valpha24+ NKT lymphocytes are activated memory cells. Eur. J. Immunol. 30 (2000) 1544-1550
33. Kadowaki N., Antonenko S., Ho S., Rissoan M.C., Soumelis V., Porcelli S.A., Lanier L.L., and Liu Y.J. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J. Exp. Med. 193 (2001) 1221-1266
34. Kim C.H., Johnston B., and Butchern E.C. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 100 (2002) 11-16
35. Thomas S.Y., Hou R., Boyson J.E., Means T.K., Hess C., Olson D.P., Strominger J.L., Brenner M.B., Gumperz J.E., Wilson S.B., and Luster A.D. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J. Immunol. 171 (2003) 2571-2580
36. Metelitsa L.S., Weinberg K.I., Emanuel P.D., and Seeger R.C. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 17 (2003) 1068-1077
37. Ikehara Y., Yasunami Y., Kodama S., Maki T., Nakano M., Nakayama T., Taniguchi M., and Ikeda S. CD4(+) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J. Clin. Invest. 105 (2000) 1761-1767
38. Seino K.I., Fukao K., Muramoto K., Yanagisawa K., Takada Y., Kakuta S., Iwakura Y., Van Kaer L., Takeda K., Nakayama T., Taniguchi M., Bashuda H., Yagita H., and Okumura K. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 2577-2581
39. Montoya C.J., Pollard D., Martinson J., Kumari K., Wasserfall C., Mulder C.B., Rugeles M.T., Atkinson M.A., Landay A.L., and Wilson S.B. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122 (2007) 1-14
40. Baev D.V., Peng X.H., Song L., Barnhart J.R., Crooks G.M., Weinberg K.I., and Metelitsa L.S. Distinct homeostatic requirements of CD4+ and CD4- subsets of Valpha24-invariant natural killer T cells in humans. Blood 104 (2004) 4150-4156
41. Sandberg J.K., Stoddart C.A., Brilot F., Jordan K.A., and Nixon D.F. Development of innate CD4+ alpha-chain variable gene segment 24 (Valpha24) natural killer T cells in the early human fetal thymus is regulated by IL-7. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 7058-7063
42. Berzins S.P., Cochrane A.D., Pellicci D.G., Smyth M.J., and Godfrey D.I. Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur. J. Immunol. 35 (2005) 1399-1407
43. Anasetti C., Amos D., Beatty P.G., Appelbaum F.R., Bensiger W., Buckner C.D., Clift R., Clift K., Doney K., Martin P.J., Mickelson E., et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N. Eng. J. Med. 320 (1989) 197-204
44. Shilling H.G., McQueen K.L., Cheng N.W., Shizuru J.A., Negrin R.S., and Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 101 (2003) 3720-3740
45. Cooley S., McCullar V., Wangen R., Bergemann T.L., Spellman S., Weisdorf D.J., and Miller J.S. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106 (2005) 4370-4376
46. Metelitsa L.S., Naidenko O.V., Kant A., Wu H.W., Loza M.J., Perussia B., Kronenberg M., and Seeger R.C. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167 (2001) 3114-3122
47. Nicol A., Nieda M., Koezuka Y., Porcelli S., Suzuki K., Tadokoro K., Durrant S., and Juji T. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 99 (2000) 229-234
48. Cutler C., and Ballen K. Reduced-intensity conditioning and umbilical cord blood transplantation in adults. Bone Marrow Trans. 44 (2009) 667-671
49. Boyson J.E., Rybalov B., Koopman L.A., Exley M.A., Balk S.P., Racke F.K., Schatz F., Masch R., Wilson S.B., and Strominger J.L. CD1d and invariant NKT cells at the human maternal-fetal interface. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13741-13746
50. Bezbradica J.S., Gordy L.E., Stanic A.K., Dragovic S., Hill T., Hawiger J., Unutmaz D., Van Kaer L., and Joyce S. Granulocyte-macrophage colony-stimulating factor regulates effector differentiation of invariant natural killer T cells during thymic ontogeny. Immunity 25 (2006) 487-497
51. Patterson S., Kotsianidis I., Almeida A., Politou M., Rahemtulla A., Matthew B., Schmidt R.R., Cerundolo V., Roberts I.A., and Karadimitris A. Human invariant NKT cells are required for effective in vitro allo-responses. J. Immunol. 175 (2005) 5087-5094
52. + NKT cells. J. Immunol. 173 (2004) 4960-4966
53. Hartung T., Docke W.D., Gantner F., Krieger G., Sauer A., Stevens P., Volk H.D., and Wendel A. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85 (1995) 2482-2489
54. Sloand E.M., Kim S., Maciejewski J.P., Kim S., Chaudhuri A., and Young N. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 95 (2000) 2269-2274
55. Shaulov A., Yue S.C., Wang R., Joyce R.M., Balk S.P., Kim H.T., Avigan D.E., Uhl L., Sackstein R., and Exley M.A. Peripheral blood progenitor cell product contains Th1-biased non-invariant CD1d-reactive natural killer T cells: implications for post-transplant survival. Exp. Hematol. 36 (2008) 464-472